{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:56:38Z","timestamp":1792166198429,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.acuroe.2026.502008","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:34:33Z","timestamp":1791286473000},"page":"502008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidisciplinary Consensus on Improving the Care Pathway for Overactive Bladder from an Adherence Perspective: The claVHes Consensus"],"prefix":"10.1016","volume":"50","author":[{"given":"A.","family":"Casteig Blanco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cornet Cortada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2026.502008_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An international urogynecological association (IUGA)\/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuroe.2026.502008_bib0010","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00192-024-06029-2","article-title":"Global prevalence of overactive bladder: a systematic review and meta-analysis","volume":"36","author":"Zhang","year":"2025","journal-title":"Int Urogynecology J"},{"key":"10.1016\/j.acuroe.2026.502008_bib0015","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00192-013-2067-1","article-title":"Assessment of female prevalence of overactive bladder (OAB) in Barcelona using a self-administered screening questionnaire: the Cuestionario de Autoevaluaci\u00f3n del Control de la Vejiga (CACV)","volume":"24","author":"Lugo Salcedo","year":"2013","journal-title":"Int Urogynecology J"},{"key":"10.1016\/j.acuroe.2026.502008_bib0020","series-title":"An\u00e1lisis nacional de la adherencia al tratamiento en patolog\u00edas cr\u00f3nicas, resultados descriptivos. Vejiga hiperactiva","author":"Ribera","year":"2017"},{"key":"10.1016\/j.acuroe.2026.502008_bib0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4321\/S0004-06142005000200006","article-title":"Prevalencia de vejiga hipertiva en Espa\u00f1a: estudio poblacional","volume":"58","author":"Castro","year":"2005","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.acuroe.2026.502008_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.61679\/1904017030","article-title":"Uso de recursos y carga socioecon\u00f3mica asociada a adultos con vejiga hiperactiva en tratamiento farmacol\u00f3gico en Espa\u00f1a. Espu\u00f1a M, editor","volume":"19","author":"Alc\u00e1ntara","year":"2024","journal-title":"Econ Salud"},{"key":"10.1016\/j.acuroe.2026.502008_bib0035","doi-asserted-by":"crossref","first-page":"181","DOI":"10.24038\/mgyf.2021.037","article-title":"Actualizaci\u00f3n en la fisiopatolog\u00eda de la vejiga hiperactiva: en el camino hacia un cambio de paradigma diagn\u00f3stico y terap\u00e9utico (I)","volume":"10","author":"Alc\u00e1ntara Montero","year":"2021","journal-title":"Med Gen Fam"},{"key":"10.1016\/j.acuroe.2026.502008_bib0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.urology.2004.10.047","article-title":"Defining overactive bladder: epidemiology and burden of disease","volume":"64","author":"Tubaro","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2026.502008_bib0045","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1464-410X.2008.07573.x","article-title":"Understanding the elements of overactive bladder: questions raised by the EPIC study","volume":"101","author":"Irwin","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.acuroe.2026.502008_bib0050","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.acuro.2009.09.001","article-title":"Impacto de la incontinencia urinaria y del s\u00edndrome de vejiga hiperactiva en la calidad de vida relacionada con la salud de pacientes de mediana edad laboralmente activos y mayores de 65 a\u00f1os institucionalizados","volume":"34","author":"Mart\u00ednez Agull\u00f3","year":"2010","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2026.502008_bib0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2009.07.1325","article-title":"Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review","volume":"75","author":"Bartoli","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2026.502008_bib0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/OAJU.S4166","article-title":"Social, economic, and health utility considerations in the treatment of overactive bladder","volume":"2","author":"Sacco","year":"2010","journal-title":"Open Access J Urol"},{"key":"10.1016\/j.acuroe.2026.502008_bib0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.acuro.2017.09.005","article-title":"Impacto de los s\u00edntomas de vejiga hiperactiva sobre la actividad laboral: estudio ACTIVHA","volume":"42","author":"Rapariz","year":"2018","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2026.502008_bib0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","article-title":"European association of urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence","volume":"82","author":"Nambiar","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.502008_bib0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.regg.2015.04.001","article-title":"Documento de consenso sobre vejiga hiperactiva en el paciente mayor","volume":"50","author":"Verdejo-Bravo","year":"2015","journal-title":"Rev Esp Geriatr\u00eda Gerontol"},{"key":"10.1016\/j.acuroe.2026.502008_bib0080","series-title":"Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical guideline","year":"2009"},{"key":"10.1016\/j.acuroe.2026.502008_bib0085","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1007\/s12325-019-01098-y","article-title":"Qualitative analysis of factors influencing patient persistence and adherence to prescribed overactive bladder medication in UK primary care","volume":"36","author":"Ali","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.acuroe.2026.502008_bib0090","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.acuroe.2026.502008_bib0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.urology.2023.09.020","article-title":"Analyzing access and costs of oral medications for overactive bladder: uncovering disparities","volume":"183","author":"Shapiro","year":"2024","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2026.502008_bib0100","series-title":"Gu\u00eda vejiga hiperactiva de la AEU [internet]","year":"2014"},{"key":"10.1016\/j.acuroe.2026.502008_bib0105","author":"Baena Gonz\u00e1lez"},{"key":"10.1016\/j.acuroe.2026.502008_bib0110","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/nau.23022","article-title":"Clinical characteristics, beliefs, and coping strategies among older patients with overactive bladder","volume":"36","author":"Blasco","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuroe.2026.502008_bib0115","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.acuroe.2026.502008_bib0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4321\/S0004-06142007000100003","article-title":"Diagn\u00f3stico y manejo de pacientes con s\u00edndrome de vejiga hiperactiva en las consultas de Urolog\u00eda y Atenci\u00f3n Primaria en Espa\u00f1a","volume":"60","author":"Garc\u00eda Matres","year":"2007","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.acuroe.2026.502008_bib0125","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/nau.24936","article-title":"Barriers and facilitators to overactive bladder therapy adherence","volume":"41","author":"Enemchukwu","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuroe.2026.502008_bib0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"212","author":"Cameron","year":"2024","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2026.502008_bib0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.euf.2025.02.006","article-title":"Antimuscarinics or \u03b23 adrenoreceptor agonists: which should be the first step?","volume":"11","author":"Gallo","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.acuroe.2026.502008_bib0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2017.01.037","article-title":"Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice","volume":"72","author":"Chapple","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.502008_bib0145","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/nau.25478","article-title":"Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: a retrospective claims study","volume":"43","author":"Chastek","year":"2024","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuroe.2026.502008_bib0150","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MBP.0000000000000572","article-title":"Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial","volume":"27","author":"Weber","year":"2022","journal-title":"Blood Press Monit"},{"key":"10.1016\/j.acuroe.2026.502008_bib0155","series-title":"Departament de Salut. Generalitat de Catalunya. Estudi d\u2019utilitzaci\u00f3 de medicaments per al tractament de la incontin\u00e8ncia urin\u00e0ria","year":"2021"},{"key":"10.1016\/j.acuroe.2026.502008_bib0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12894-021-00812-9","article-title":"Clustering of patients with overactive bladder syndrome","volume":"21","author":"Gross","year":"2021","journal-title":"BMC Urol"},{"key":"10.1016\/j.acuroe.2026.502008_bib0165","first-page":"904","article-title":"Phenotyping overactive bladder \u2013 part 2: can management be improved by phenotyping, and targeting therapy according to urgency type and other characteristics? ICI-RS 2025","author":"Wyndaele","year":"2025","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuroe.2026.502008_bib0170","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00192-017-3481-6","article-title":"Development of a core set of outcome measures for OAB treatment","volume":"28","author":"Foust-Wright","year":"2017","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.acuroe.2026.502008_bib0175","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/nau.25307","article-title":"Exploring lifelong overactive bladder: transitions, evidence, and clinical implications; A modified Delphi process","volume":"43","author":"Bou Kheir","year":"2024","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuroe.2026.502008_bib0180","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00228-012-1419-y","article-title":"Nurse-led interventions to enhance adherence to chronic medication: systematic review and meta-analysis of randomised controlled trials","volume":"69","author":"Van Camp","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.acuroe.2026.502008_bib0185","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-089006","article-title":"Low-value practices in primary care: a cross-sectional study comparing data between males and females in Spain","volume":"14","author":"Mira","year":"2024","journal-title":"BMJ Open"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578626001368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578626001368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:32:09Z","timestamp":1792164729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578626001368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2173578626001368"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2026.502008","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidisciplinary Consensus on Improving the Care Pathway for Overactive Bladder from an Adherence Perspective: The claVHes Consensus","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2026.502008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2026.502008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a S.L.U. on behalf of Asociaci\u00f3n Espa\u00f1ola de Urolog\u00eda (AEU), by Sociedad Espa\u00f1ola de Ginecolog\u00eda y Obstetricia and Sociedad Espa\u00f1ola de M\u00e9dicos Generales y de Familia (SEMG).","name":"copyright","label":"Copyright"}],"article-number":"502008"}}